Ind-Swift Laboratories Ltd
- P/E
- 50.9x
- 52-week range
- 87.15 – 424.75
- ROE
- 4%
- ROCE
- 5%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Ind-Swift Laboratories Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)50.9 against a typical 34.6: pricier than most peers (1st = cheapest).158th of 220
- Sales growth+24.8% against a typical +15.6% from a year earlier.68th of 197
- Profit growth+177.8% against a typical +18.9% from a year earlier.20th of 160
- Share price, 3 months+68.8% against a typical −0.5%.7th of 200
Latest announcements
Exchange filings and their impact on the company.
- Promoter group converted 14 lakh warrants at Rs196, bringing Rs20.58 cr cash with 1.6% dilution.
Ind-Swift Laboratories allotted 14 lakh equity shares at Rs196 each on conversion of 14 lakh warrants to promoter-group Essix Biosciences, out of 70 lakh warrants issued on 17 September 2026. The company received the balance Rs147 per warrant, totalling Rs20.58 crore. Paid-up capital rose to 8.69 crore shares from 8.67 crore shares, bringing in cash with modest dilution.
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 8 Oct 2026 | Warrant conversion | Allotted | ₹ 20.58 Cr. | ₹ 196 | +92.55% |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | Board meeting intimation to consider and approve the financial results for the period ended Jun 30, 2026 |
| 10 Jul 2026 | Fund Raising | Intimation of Meeting of the Board of Directors pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. |
| 28 May 2026 | Financial Results | To consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026 |
| 31 Jan 2026 | Financial Results | To consider and approve, inter alia, the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 |
| Expenses | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 |
| Operating Profit | 66 | 52 | 91 | −10 | −12 | −7 | −9 | 4 | 1 | 4 | 21 | 33 |
| OPM % | 23% | 18% | 17% | −29% | −99% | −5% | −7% | 2.4% | 1% | 2.8% | 12% | 17% |
| Other Income | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | −3 | 7 |
| Interest | 21 | 21 | 3 | 0 | 0 | 10 | −27 | 1 | 2 | 1 | −2 | 1 |
| Depreciation | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 |
| Profit before tax | 39 | 24 | 527 | 1 | 1 | −7 | 230 | 10 | 10 | 16 | 12 | 33 |
| Tax % | 18% | 19% | 6% | −3% | 31% | −16% | 4% | 17% | 22% | 42% | −26% | 25% |
| Net Profit | 32 | 19 | 494 | 1 | 0 | −5 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS in Rs | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | −0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- −6%
- 3 Years
- −19%
- TTM
- 54%
- 10 Years
- 12%
- 5 Years
- 78%
- 3 Years
- −7%
- TTM
- 195%
- 10 Years
- 25%
- 5 Years
- 40%
- 3 Years
- 55%
- TTM
- —
- 10 Years
- 3%
- 5 Years
- 6%
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Ind-Swift Laboratories Ltd | ₹ 377.40 | — | 50.9x | — | 4% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Navrattan R. Munjal
- Executive Chairman of the Board, Managing Director
- Gagan Aggarwal
- Chief Financial Officer
- Varun Chhabra
- Senior Vice President - Marketing
- Ashok Prasad
- Senior Vice President - R&D
- Pardeep Verma
- Compliance Officer, Vice President - Corporate Affairs, Company Secretary
- Himanshu Jain
- Joint Managing Director, Whole Time Director
- Rishav Mehta
- Executive Director
- Sahil Munjal
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.